Starfire Investment Advisers adds IsoRay (ISR) to its portfolio

IsoRay (ISR) : Starfire Investment Advisers added new position in IsoRay during the most recent quarter end. The investment management firm now holds 21,285 shares of IsoRay which is valued at $14,900 , the company said in a statement filed on Oct 17, 2016 with the SEC.IsoRay makes up approximately 0.01% of Starfire Investment Advisers’s portfolio.

Other Hedge Funds, Including ,

IsoRay closed down -0.0001 points or -0.01% at $0.7 with 1,25,130 shares getting traded on Friday. Post opening the session at $0.7001, the shares hit an intraday low of $0.7 and an intraday high of $0.7099 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

IsoRay Inc. develops manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in treatment for all solid tumors using Cesium-131. Cesium-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130 (Ba-130). The Company’s product candidate is Proxcelan Cesium-131. The Company markets the Proxcelan Cesium-131 brachytherapy seed for the treatment of prostate cancer; brain cancer; lung cancer; head and neck cancers; gynecological cancer: pelvic/abdominal cancer; colorectal cancer and ocular melanoma. It also markets the GliaSite RTS for the treatment of brain cancer such as primary and recurrent gliomas and metastic brain tumors. GliaSite RTS is a cleared balloon catheter device. The components included in the GliaSite RTS are the GliaSite Catheter Tray GliaSite Access Tray Iotrex Solidifier and either Iotrex or Cesitrex as the radiotherapy solution.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *